Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data

References

• Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619–29
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005;16:1569–83
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology – Version 2.2006. 12-5-05 ©2005 National Comprehensive Cancer Network, Inc.
   Google Scholar
• Howell A; on behalf of the ATAC Trialists’ Group. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer updated efficacy results based on a median follow-up of 5 years. Lancet 2005;365: 1225–6
   Google Scholar
• Thürlimann B, Keshaviah A, Coates AS, et al.; the Breast International Group (BIG) 1–98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 2005;353: 2747–57
   Google Scholar
• Coombes RC, Paridaens R, Jassem J, et al.; for the Intergroup Exemestane Study (IES). First mature analysis of the Intergroup Exemestane Study. J Clin Oncol 2006;24(18S):933s [abstract LBA527]
   Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738–46
   Google Scholar
• McArthur HL, Olivotto I, Gelmon KA, et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res Treat 2005;94\(Suppl 1):S124 [abstract 3001]
   Google Scholar
• Baum M, Buzdar A, Cuzick J, et al.; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802–10
   Google Scholar
• Howell A. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 5 years. Presented at the 24th Annual San Antonio Breast Cancer Symposium, December 2004 [poster 1]
   Google Scholar
• Anastrozole (Arimidex) package insert. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, 2005
   Google Scholar
• Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512–7
   PubMed Web of Science ®Google Scholar
• Viale G, Regan M, Dell’Orto P, et al. Central review of ER, PgR and HER-2 in BIG 1–98 evaluating letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005:94\(Suppl 1):S13 [abstract 44]
   Google Scholar
• Jakesz R, Jonat W, Gnant M, et al.; on behalf of the ABCSG, the GABG. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366: 455–62
   Google Scholar
• Letrozole (Femara) package insert. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, 2005
   Google Scholar
• Letrozole European SPC. 2006. Available at: http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc.asp&documentid=3845
   Google Scholar
• Exemestane (Aromasin) package insert. Pfizer Inc, New York, NY, 2005
   Google Scholar
• Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005;23;5138–47
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 2005;41:1678–89 [Epub November 25, 2004]
   Google Scholar
• Jonat W, Gnant M, Boccardo F, et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. Breast Cancer Res Treat 2005;94\(Suppl 1):S11 [abstract 18]
   Google Scholar
• Coombes RC, Hall E, Snowdon CF, Bliss JM. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 2004;88:S7 [abstract 3]
   Google Scholar
• Pritchard KI. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen. J Clin Oncol 2005;23:4850–2 [Epub July 11, 2005]
   Google Scholar
• Jakesz R, Gnant M, Greil R, et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 2005;94 (Suppl 1):S10 [abstract 13]
   Google Scholar
• Howell A, Cuzick J. Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol 2005;95:143–9 [erratum in: J Steroid Biochem Mol Biol 2006;98:180 (Epub June 2, 2005)]
   Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–71
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937–47
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365: 1687–717
   Google Scholar
• Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Women’s Health Issues 2001;11:95–102
   PubMed Web of Science ®Google Scholar
• McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial [The Scottish Cancer Trials Breast Group]. Br Med J 1995;311:977–80
   PubMed Web of Science ®Google Scholar
• Nordenskjold B, Rosell J, Rutqvist LE, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005;97:1609–10
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261–71
   PubMed Web of Science ®Google Scholar
• Distler W.; on behalf of the ATAC Trialists’ Group. Safety and tolerability data from the ATAC trial after completion of 5 years adjuvant treatment. Breast 2005;14\(Suppl 1):S51 [abstract P128]
   Google Scholar
• Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006;24:910–7
   PubMed Web of Science ®Google Scholar
• Medical Review of ATAC. Approval Package for Application Number 20–541/ S–010. Anastrozole Efficacy Supplement Clinical Review 2002. [part 1; page 19 available at: http://www.fda.gov/cder/foi/nda/2002/20-541s010_Arimidex.htm] [accessed April 14, 2006]
   Google Scholar
• Houghton J.; on behalf of the ATAC Trialists’ Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. J Clin Oncol 2005:23\(Suppl 16):24S [abstract 582]
   Google Scholar
• Punglia RS, Kuntz KM, Winer EP, et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005;23:5178–87 [Epub July 5, 2005]
   Google Scholar
• Cuzick J, Howell A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. J Clin Oncol 2005;25(16 Suppl):43S [abstract 658]
   Google Scholar
• Hilsenbeck SG, Osborne CK. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res 2006;12:1049s–1055s
   Google Scholar
• Cykert S, Phifer N, Hansen C. Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol 2004;104:433–42
   Google Scholar
• Karnon J, Delea TE, Barghout V, et al. Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the UK perspective. Breast Cancer Res Treat 2005;94\(Suppl 1):S104 [abstract 2058]
   Google Scholar
• Thompson D, Taylor DCA, Montoya EL, et al. Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer. Breast Cancer Res Treat 2005;94\(Suppl 1): S218 [abstract 5037]
   Google Scholar
• Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004;101:1311–22
   PubMed Web of Science ®Google Scholar
• Younis T, Rayson D, Dewar R, Skedgel C. Modeling for cost-effective strategies in adjuvant hormonal therapy for postmenopausal women with breast cancer: upfront aromatase inhibitors vs sequential tamoxifen-aromatase inhibitors. Breast Cancer Res Treat 2005;94\(Suppl 1):S237 [abstract 5089]
   Google Scholar
• Delea TE, Karnon J, Thomas SK, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective. Breast Cancer Res Treat 2005;94\(Suppl 1):S102 [abstract 2054]
   Google Scholar
• Risebrough NA, Verma S, Trudeau M, et al. Economic evaluation of switching to exemestane at 2.5 years versus continuing tamoxifen as adjuvant therapy in early breast cancer: a Canadian perspective. Breast Cancer Res Treat 2005;94\(Suppl 1): S101 [abstract 2050]
   Google Scholar
• Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2005;17:217–25 [Epub Nov 2, 2005]
   Google Scholar
• De Boer R, Burris H, Monnier A, et al.; on behalf of the H2H Trial Steering Committee. The head to head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. Proc Am Soc Clin Oncol 2006;24:582s [abstract 10672]
   Google Scholar